Article

Segment 4- Nonadherence Caused by a Lack of Access

In this portion of the panel discussion, Dr Fendrick asked the panel whether or not they have noticed cost-related lack of access or nonadherence with the new agents being discussed.

In this portion of the panel discussion, Dr Fendrick asked the panel whether or not they have noticed cost-related lack of access or nonadherence with the new agents being discussed. “It’s certainly happening for ipilimumab,” said Dr Ribas. “In places like the county hospital it’s hard to find any patient who has been on ipilimumab because it’s not being approved for administration even though it’s an FDA-approved drug and even though there are 2 randomized trials that demonstrated improvement in survival.”

Related Videos
Caspian Oliai, MD, MS, a medical oncologist and hematologist and medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Anna Mueller, MD, Mount Sinai
John Ostrominski, MD
Marc P. Bonaca, MD, MPH
Christian T. Ruff, MD, MPH
Jaime Murillo, MD
Ajai Chari, MD
Charles C. Wykoff, MD, PhD
Dr Charles Wykoff
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo